Literature DB >> 2541844

Measurement of 3-methoxy-4-hydroxyphenylglycol (MHPG) in mouse brain by h.p.l.c. with electrochemical detection, as an index of noradrenaline utilisation and presynaptic alpha 2-adrenoceptor function.

D J Heal1, M R Prow, W R Buckett.   

Abstract

1. A novel method for measurement of 3-methoxy-4-hydroxyphenylglycol (MHPG) in mouse brain by use of high performance liquid chromatography (h.p.l.c.) with electrochemical detection is described. This technique incorporates an ethyl acetate purification procedure and uses 3-hydroxy-4-methoxyphenylglycol (iso-MHPG) as the internal standard. 2. Inhibition of monoamine oxidase by injection of tranylcypromine (5 and 10 mg kg-1) or pargyline (50 and 100 mg kg-1) markedly decreased brain MHPG concentrations. After injection of the tyrosine hydroxylase inhibitor, alpha-methyl-p-tyrosine (200 mg kg-1), there were time-dependent linear decreases in the concentrations of noradrenaline and MHPG in mouse brain. In addition, a very good correlation (r = 0.95, n = 30; P less than 0.001) was found between the concentrations of noradrenaline and MHPG present in the brains of the same mice after alpha-methyl-p-tyrosine treatment. 3. Mouse brain MHPG concentrations were dose-dependently reduced after administration of the alpha 2-adrenoceptor agonist, clonidine (1-3000 micrograms kg-1), and elevated by the antagonists, idazoxan (1 and 5 mg kg-1), and yohimbine (1 and 5 mg kg-1). Intracerebroventricular injection of the alpha 1-adrenoceptor agonist, phenylephrine (5-50 micrograms) dose-dependently increased MHPG levels. The alpha 1-adrenoceptor antagonist, prazosin, had no effect at the moderate dose of 1 mg kg-1, but increased MHPG concentrations at 5 mg kg-1. The beta-adrenoceptor agonist, clenbuterol (10-1000 micrograms kg-1) and the antagonist, pindolol (1 and 5 mg kg-1), were both without effect. 4. The decrease in brain MHPG concentrations induced by clonidine (100 micrograms kg-1) was prevented by prior injection of 1 mg kg-1 of idazoxan or yohimbine, but not by prazosin or pindolol. 5. MHPG levels were decreased after administration of the noradrenaline reuptake inhibitor desipramine (5 and 10 mg kg-1) and the non-selective monoamine reuptake inhibitors, sibutramine HCl (BTS 54 524; 1 and 3 mg kg-1) and amitryptyline (5 mg kg-1). However, the selective 5-hydroxytryptamine reuptake inhibitor, zimeldine (5 and 10 mg kg-1), was without effect. Dexamphetamine (1 and 5 mg kg-1) and methamphetamine (1 and 5 mg kg-1) both decreased brain MHPG concentrations in a dose-related fashion. 6. Overall the data show that MHPG can be used as a functional index of both presynaptic alpha 2-adrenoceptor activity and noradrenaline turnover and utilisation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2541844      PMCID: PMC1854396          DOI: 10.1111/j.1476-5381.1989.tb11852.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

1.  (Z)-dimethylamino-1-(4-bromophenyl)-1-(3-pyridyl) propene (h 102/09), a new selective inhibitor of the neuronal 5-hydroxytryptamine uptake.

Authors:  S B Ross; S O Ogren; A L Renyi
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1976-08

2.  Different alpha-adrenoreceptors in the central nervous system mediating biochemical and functional effects of clonidine and receptor blocking agents.

Authors:  N E Andén; M Grabowska; U Strömbom
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976       Impact factor: 3.000

Review 3.  Simple neuronal models to estimate turnover rate of noradrenergic transmitters in vivo.

Authors:  E Costa
Journal:  Adv Biochem Psychopharmacol       Date:  1970

4.  Involvement of nigro-striatal neurons in the in vivo release of dopamine by amphetamine, amantadine and tyramine.

Authors:  P F Von Voigtlander; K E Moore
Journal:  J Pharmacol Exp Ther       Date:  1973-03       Impact factor: 4.030

5.  d-Amphetamine as a releaser or reuptake inhibitor of biogenic amines in synaptosomes.

Authors:  M Raiteri; A Bertollini; F Angelini; G Levi
Journal:  Eur J Pharmacol       Date:  1975-11       Impact factor: 4.432

6.  Application of steady state kinetics to the estimation of synthesis rate and turnover time of tissue catecholamines.

Authors:  B B Brodie; E Costa; A Dlabac; N H Neff; H H Smookler
Journal:  J Pharmacol Exp Ther       Date:  1966-12       Impact factor: 4.030

7.  Fluorometric estimation of 4-hydroxy-3-methoxyphenylethyleneglycol sulphate in brain.

Authors:  J L Meek; N H Neff
Journal:  Br J Pharmacol       Date:  1972-07       Impact factor: 8.739

8.  Behavioural and biochemical evidence for the release of noradrenaline in mouse brain by TRH and some of its biologically stable analogues.

Authors:  D J Heal; N Stoodley; J M Elliott; C A Marsden; G W Bennett; M B Youdim
Journal:  Neuropharmacology       Date:  1987-04       Impact factor: 5.250

9.  Glycol metabolites of noradrenaline in brain tissue.

Authors:  D F Sharman
Journal:  Br J Pharmacol       Date:  1969-07       Impact factor: 8.739

10.  Studies on the metabolism of catecholamines in the central nervous system of the mouse.

Authors:  P M Ceasar; P Hague; D F Sharman; B Werdinius
Journal:  Br J Pharmacol       Date:  1974-06       Impact factor: 8.739

View more
  15 in total

1.  Poster communications.

Authors: 
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

2.  Differential encoding of signals and preferences by noradrenaline in the anuran brain.

Authors:  Sabrina S Burmeister; Verónica G Rodriguez Moncalvo; Karin S Pfennig
Journal:  J Exp Biol       Date:  2020-09-21       Impact factor: 3.312

3.  Extracellular brain cortical levels of noradrenaline in ischemia: effects of desipramine and postischemic administration of idazoxan.

Authors:  I Gustafson; E J Westerberg; T Wieloch
Journal:  Exp Brain Res       Date:  1991       Impact factor: 1.972

4.  MicroRNA-19b associates with Ago2 in the amygdala following chronic stress and regulates the adrenergic receptor beta 1.

Authors:  Naama Volk; Evan D Paul; Sharon Haramati; Chen Eitan; Brandon K K Fields; Raaya Zwang; Shosh Gil; Christopher A Lowry; Alon Chen
Journal:  J Neurosci       Date:  2014-11-05       Impact factor: 6.167

5.  The involvement of noradrenergic transmission in the morphine-induced locomotor hyperactivity in mice withdrawn from repeated morphine treatment.

Authors:  J Airio; L Ahtee
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

6.  Evidence that RU 24969-induced locomotor activity in C57/B1/6 mice is specifically mediated by the 5-HT1B receptor.

Authors:  S C Cheetham; D J Heal
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

7.  Alpha 2-autoreceptor-mediated modulation of tyrosine hydroxylase activity in noradrenergic regions of the rat brain in vivo.

Authors:  F Pi; J A García-Sevilla
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-06       Impact factor: 3.000

8.  A comparison of various antidepressant drugs demonstrates rapid desensitisation of alpha 2-adrenoceptors exclusively by sibutramine hydrochloride.

Authors:  D J Heal; M R Prow; J Gosden; G P Luscombe; W R Buckett
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

9.  Effects of antidepressant drugs and electroconvulsive shock on pre- and postsynaptic alpha 2-adrenoceptor function in the brain: rapid down-regulation by sibutramine hydrochloride.

Authors:  D J Heal; M R Prow; W R Buckett
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

10.  Changes induced by sodium cromoglycate in brain catecholamine turnover in morphine dependent and abstinent mice.

Authors:  O San-Martín-Clark; B Cuéllar; J De Alba; J C Leza; P Lorenzo
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.